- Home
- ALEC vs NRXP Comparison
ALEC vs NRXP Comparison
Compare ALEC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 153.2M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALEC | NRXP |
|---|---|---|
| Price | $2.03 | $3.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.83 | ★ $38.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,045,000.00 | $1,225,000.00 |
| Revenue This Year | $2.03 | $2,547.84 |
| Revenue Next Year | $29.87 | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $1.65 |
| 52 Week High | $3.40 | $5.06 |
Technical Indicators
Market Signals| Indicator | ALEC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 40.93 |
| Support Level | $1.93 | $2.88 |
| Resistance Level | $2.10 | $3.33 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 81.94 | 30.83 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.